Derek V. Exner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Derek V. Exner has a total of 345 co-authors. Here are the top co-authors by number of shared publications:
- Derek S. Chew
Department of Cardiac Sciences, Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada
8 shared publications - James E. Ip
Department of Medicine, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York
6 shared publications - Rahul N. Doshi
HonorHealth Cardiac Arrhythmia Group, Scottsdale, AZ (R.D.).
6 shared publications - Vivek Y. Reddy
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York
6 shared publications - Gerhard Hindricks
Deutsches Herzzentrum der Charité (DHZC), Berlin, Germany
5 shared publications - Mayer Rashtian
Huntington Memorial Hospital, Pasadena, CA (M.R.).
5 shared publications
Latest Publications
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (1) , e014132
4D Digital Heart Model–Guided Left and Right Ventricular Lead Placement for Cardiac Resynchronization Therapy: Results of MAPIT-CRT Trial
BACKGROUND: Suboptimal left ventricular (LV) and right ventricular lead positioning has been associated with a lesser response to cardiac resynchronization therapy. The MAPIT-CRT (MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy) randomized controlled trial evaluated a novel, cardiac magnetic resonance–generated 4-dimensional phenomics cardiac magnetic resonance imaging (4DPcmr) lead placement strategy. METHODS: A total of 202 participants with New York Heart Association class II to IV heart failure on optimal medical therapy, LV ejection fraction ≤35%, and QRS duration ≥120 ms were analyzed from 7 Canadian sites. Participants were randomized to 4DPcmr-guided lead placement using a web-based application or standard lead placement. 4DPcmr-recommended LV and right ventricular (RV) lead locations were generated using the combined consideration of (1) regional scar distribution and burden, (2) maximal regional delay in LV peak systolic strain, and (3) maximal interlead distance. RESULTS: The primary end point, an increase in LV ejection fraction ≥5% at 6 months, was reached in 69 of 105 4DPcmr-guided participants (65.7%) versus 50 of 96 control participants (52.1%; risk ratio, 1.80 [95% CI, 1.02–3.17]; P =0.04). The absolute increases in LV ejection fraction observed for the respective study arms were 10.8% versus 5.8% ( P =0.01). No differences were identified in the secondary end points of all-cause mortality or heart failure hospitalization at 12 months, rate of adverse outcomes, or procedural times between the 2 study arms. CONCLUSIONS: 4DPcmr-guided LV/RV cardiac resynchronization therapy lead implantation using a practical web application was clinically feasible, safe, and was associated with greater LV ejection fraction improvement at 6 months versus standard of care with no increase in procedural times or complications. REGISTRATION: URL: https://clinicaltrials.gov/study/NCT01640769 ; Unique identifier: NCT01640769.
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (1) , e014132
4D Digital Heart Model–Guided Left and Right Ventricular Lead Placement for Cardiac Resynchronization Therapy: Results of MAPIT-CRT Trial
BACKGROUND: Suboptimal left ventricular (LV) and right ventricular lead positioning has been associated with a lesser response to cardiac resynchronization therapy. The MAPIT-CRT (MRI Allocation of Pacing Targets in Cardiac Resynchronization Therapy) randomized controlled trial evaluated a novel, cardiac magnetic resonance–generated 4-dimensional phenomics cardiac magnetic resonance imaging (4DPcmr) lead placement strategy. METHODS: A total of 202 participants with New York Heart Association class II to IV heart failure on optimal medical therapy, LV ejection fraction ≤35%, and QRS duration ≥120 ms were analyzed from 7 Canadian sites. Participants were randomized to 4DPcmr-guided lead placement using a web-based application or standard lead placement. 4DPcmr-recommended LV and right ventricular (RV) lead locations were generated using the combined consideration of (1) regional scar distribution and burden, (2) maximal regional delay in LV peak systolic strain, and (3) maximal interlead distance. RESULTS: The primary end point, an increase in LV ejection fraction ≥5% at 6 months, was reached in 69 of 105 4DPcmr-guided participants (65.7%) versus 50 of 96 control participants (52.1%; risk ratio, 1.80 [95% CI, 1.02–3.17]; P =0.04). The absolute increases in LV ejection fraction observed for the respective study arms were 10.8% versus 5.8% ( P =0.01). No differences were identified in the secondary end points of all-cause mortality or heart failure hospitalization at 12 months, rate of adverse outcomes, or procedural times between the 2 study arms. CONCLUSIONS: 4DPcmr-guided LV/RV cardiac resynchronization therapy lead implantation using a practical web application was clinically feasible, safe, and was associated with greater LV ejection fraction improvement at 6 months versus standard of care with no increase in procedural times or complications. REGISTRATION: URL: https://clinicaltrials.gov/study/NCT01640769 ; Unique identifier: NCT01640769.
- 1 April 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (4) , e013619
One-Year Safety and Performance of a Dual-Chamber Leadless Pacemaker
BACKGROUND: A dual-chamber leadless pacemaker can provide bradycardia therapy to most patients with pacemaker indications without the complications associated with a lead or pulse generator. We sought to confirm whether previously reported 3-month safety and performance outcomes were sustained through 12 months by determining whether 12-month complication-free and performance success rates exceeded their prespecified performance goals. METHODS: Patients were enrolled in the prospective, single-group Aveir DR i2i Study if they had a standard indication for dual-chamber pacing. Enrolled patients were implanted with an Aveir DR dual-chamber leadless pacemaker system, which comprised 2 communicating leadless pacemakers (1 in the right atrium and 1 in the right ventricle). The primary safety outcome evaluated whether freedom from serious device- or procedure-related events through 365 days exceeded the predetermined performance goal of 76.5%. The primary performance outcome determined whether the composite of atrial capture threshold (≤3.0 V at 0.4 ms) and sensing amplitude (P-wave ≥1.0 mV) at the 12-month visit exceeded the predetermined performance goal of 80.0%. RESULTS: Sites attempted implantation in 300 subjects, where 63.3% had sinus-node dysfunction and 33.3% had atrioventricular block as their primary pacing indication. The primary safety end point was achieved, with a Kaplan-Meier 12-month complication-free rate of 88.6% (95% CI, 84.5–91.8; P P <0.001). CONCLUSIONS: Both primary safety and performance end points were met after 1 year, demonstrating consistency with previously reported 3-month outcomes of a dual-chamber leadless pacemaker. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05252702.
- 1 April 2025
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 18 (4) , e013619
One-Year Safety and Performance of a Dual-Chamber Leadless Pacemaker
BACKGROUND: A dual-chamber leadless pacemaker can provide bradycardia therapy to most patients with pacemaker indications without the complications associated with a lead or pulse generator. We sought to confirm whether previously reported 3-month safety and performance outcomes were sustained through 12 months by determining whether 12-month complication-free and performance success rates exceeded their prespecified performance goals. METHODS: Patients were enrolled in the prospective, single-group Aveir DR i2i Study if they had a standard indication for dual-chamber pacing. Enrolled patients were implanted with an Aveir DR dual-chamber leadless pacemaker system, which comprised 2 communicating leadless pacemakers (1 in the right atrium and 1 in the right ventricle). The primary safety outcome evaluated whether freedom from serious device- or procedure-related events through 365 days exceeded the predetermined performance goal of 76.5%. The primary performance outcome determined whether the composite of atrial capture threshold (≤3.0 V at 0.4 ms) and sensing amplitude (P-wave ≥1.0 mV) at the 12-month visit exceeded the predetermined performance goal of 80.0%. RESULTS: Sites attempted implantation in 300 subjects, where 63.3% had sinus-node dysfunction and 33.3% had atrioventricular block as their primary pacing indication. The primary safety end point was achieved, with a Kaplan-Meier 12-month complication-free rate of 88.6% (95% CI, 84.5–91.8; P P <0.001). CONCLUSIONS: Both primary safety and performance end points were met after 1 year, demonstrating consistency with previously reported 3-month outcomes of a dual-chamber leadless pacemaker. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05252702.
- Open Access
- 6 August 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (6) , 439-450
Atrioventricular Synchrony Delivered by a Dual-Chamber Leadless Pacemaker System
BACKGROUND: A dual-chamber leadless pacemaker system has been designed for atrioventricular synchronous pacing using wireless, beat-to-beat, implant-to-implant (i2i) communication between distinct atrial and ventricular leadless pacemakers. The atrioventricular synchrony achieved across various ambulatory scenarios has yet to be systematically evaluated. METHODS: A prospective, single-arm, unblinded, multicenter, international clinical trial of the leadless pacemaker system was conducted in patients with a conventional dual-chamber pacing indication enrolled from February 2022 to March 2023. Leadless pacemaker systems were implanted, and 12-lead Holter electrocardiographic recordings were collected 3 months after implantation over various postures/activities: sitting, supine, left lateral recumbent, right lateral recumbent, standing, normal walk, and fast walk. An independent Holter core laboratory performed a manual adjudication of the percent of atrioventricular synchronous beats using the standard 300-millisecond PR interval limit. Atrium-to-ventricle and ventricle-to-atrium i2i communication success rates were also assessed. Post hoc summary statistics describing the relationships between atrioventricular synchrony and i2i success, posture/activity, implantation indication, atrioventricular event, and heart rate were calculated. RESULTS: In the evaluable population (n=384 of 464 enrolled [83%]; 61% male; age, 70 years; weight, 82 kg; 60% ejection fraction; 95% of beats evaluable), the mean atrioventricular synchrony of 98% of beats observed across all postures using the standard 300-millisecond limit was greater than both atrial-to-ventricular i2i (94%) and ventricular-to-atrial i2i (94%; P 95% of evaluable beats across all postures/activities, implantation indications, atrioventricular paced/sensed event combinations, and heart rate ranges (including >100 bpm). CONCLUSIONS: This dual-chamber leadless pacemaker system demonstrated atrioventricular synchrony in 98% of evaluable beats at 3 months after implantation. Atrioventricular synchrony was maintained across postures/activities and remained robust for heart rates >100 bpm.
- 6 August 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (6) , 439-450
Open AccessAtrioventricular Synchrony Delivered by a Dual-Chamber Leadless Pacemaker System
BACKGROUND: A dual-chamber leadless pacemaker system has been designed for atrioventricular synchronous pacing using wireless, beat-to-beat, implant-to-implant (i2i) communication between distinct atrial and ventricular leadless pacemakers. The atrioventricular synchrony achieved across various ambulatory scenarios has yet to be systematically evaluated. METHODS: A prospective, single-arm, unblinded, multicenter, international clinical trial of the leadless pacemaker system was conducted in patients with a conventional dual-chamber pacing indication enrolled from February 2022 to March 2023. Leadless pacemaker systems were implanted, and 12-lead Holter electrocardiographic recordings were collected 3 months after implantation over various postures/activities: sitting, supine, left lateral recumbent, right lateral recumbent, standing, normal walk, and fast walk. An independent Holter core laboratory performed a manual adjudication of the percent of atrioventricular synchronous beats using the standard 300-millisecond PR interval limit. Atrium-to-ventricle and ventricle-to-atrium i2i communication success rates were also assessed. Post hoc summary statistics describing the relationships between atrioventricular synchrony and i2i success, posture/activity, implantation indication, atrioventricular event, and heart rate were calculated. RESULTS: In the evaluable population (n=384 of 464 enrolled [83%]; 61% male; age, 70 years; weight, 82 kg; 60% ejection fraction; 95% of beats evaluable), the mean atrioventricular synchrony of 98% of beats observed across all postures using the standard 300-millisecond limit was greater than both atrial-to-ventricular i2i (94%) and ventricular-to-atrial i2i (94%; P 95% of evaluable beats across all postures/activities, implantation indications, atrioventricular paced/sensed event combinations, and heart rate ranges (including >100 bpm). CONCLUSIONS: This dual-chamber leadless pacemaker system demonstrated atrioventricular synchrony in 98% of evaluable beats at 3 months after implantation. Atrioventricular synchrony was maintained across postures/activities and remained robust for heart rates >100 bpm.
- Open Access
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Upgrading a single-chamber leadless pacemaker to a dual-chamber leadless pacemaker system
Background/Introduction: The first global dual-chamber leadless pacemaker (DR-LP) study included a group of subjects with a pre-existing upgradeable ventricular single chamber leadless pacemaker (VR-LP) in whom the addition of an atrial leadless pacemaker (AR-LP) was undertaken to allow upgrading to a dual chamber leadless pacing (DR-LP) system. Purpose: Summarize success rates of single to dual chamber leadless pacemaker upgrades, as well as device and i2i throughput measurements, serious adverse device effects (SADEs) and mortality in this cohort. Methods: Subjects with a pre-existing VR-LP who were indicated for a dual-chamber pacemaker were included. Upgrade procedures included downloading firmware to existing VR-LP, placing AR-LP, and pairing the devices to operate in a DR-LP mode. Electrical and i2i throughput measurements were collected at implant, pre-discharge, 1-mo, 3-mo, 6-mo, and 12-mo. Upgrade success rate was defined as an AR-LP upgrade procedure that resulted in a functional DR-LP system. SADEs included all reported events that were adjudicated as serious and possibly, probably or causally related to the procedure or system. SADEs and deaths were adjudicated by an independent clinical events committee. Results: Out of 36 enrolled subjects (61.1% male, 70.4 ± 13.8 yrs., 55.6% sinus node dysfunction, 38.9% AV block), 35 had an attempted implant, and 32 of these were successful (91.4%). The 3 unsuccessful upgrade attempts were related to unsuccessful placement of the AR-LP due to complications during the procedure (n = 2) or an inability to implant an AR-LP (n = 1). Figure 1 illustrates a declining early mean pacing capture threshold, rising early P-wave amplitudes, and stable impedance for the AR-LP over the 12 months. Mean i2i throughput for communication from the RV to RA and the RA to RV improved from pre-discharge to 3 months and remained stable through the subsequent 9 months (Figure 2). A total of 5 subjects (5 of 36; 13.9%) experienced 7 SADEs (all procedure-related; 2 related to the AR-LP and 2 to the delivery catheter). One non-cardiovascular, non-device, non-procedure related death occurred in the upgrade population. Conclusions: The single to dual-chamber upgrade cohort demonstrated a high upgrade success rate (91.4%), stable atrial and ventricular electrical measurements and consistently high i2i communication throughout the 12 months. AV synchrony (AVS) was not specifically measured in this upgrade cohort, but data from the main DR-LP study suggest that i2i throughput correlates with, but significantly underestimates AVS. Further, the rate of complications was acceptable (13.9%) and limited to the procedure. These data confirm the feasibility, safety and longer-term effectiveness of adding an atrial LP in patients with a pre-existing ventricular LP order to achieve effective dual chamber pacing.Fig. 1: Upgrade Electrical measurementsFig. 2: i2i communication for Upgrades
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Open AccessUpgrading a single-chamber leadless pacemaker to a dual-chamber leadless pacemaker system
Background/Introduction: The first global dual-chamber leadless pacemaker (DR-LP) study included a group of subjects with a pre-existing upgradeable ventricular single chamber leadless pacemaker (VR-LP) in whom the addition of an atrial leadless pacemaker (AR-LP) was undertaken to allow upgrading to a dual chamber leadless pacing (DR-LP) system. Purpose: Summarize success rates of single to dual chamber leadless pacemaker upgrades, as well as device and i2i throughput measurements, serious adverse device effects (SADEs) and mortality in this cohort. Methods: Subjects with a pre-existing VR-LP who were indicated for a dual-chamber pacemaker were included. Upgrade procedures included downloading firmware to existing VR-LP, placing AR-LP, and pairing the devices to operate in a DR-LP mode. Electrical and i2i throughput measurements were collected at implant, pre-discharge, 1-mo, 3-mo, 6-mo, and 12-mo. Upgrade success rate was defined as an AR-LP upgrade procedure that resulted in a functional DR-LP system. SADEs included all reported events that were adjudicated as serious and possibly, probably or causally related to the procedure or system. SADEs and deaths were adjudicated by an independent clinical events committee. Results: Out of 36 enrolled subjects (61.1% male, 70.4 ± 13.8 yrs., 55.6% sinus node dysfunction, 38.9% AV block), 35 had an attempted implant, and 32 of these were successful (91.4%). The 3 unsuccessful upgrade attempts were related to unsuccessful placement of the AR-LP due to complications during the procedure (n = 2) or an inability to implant an AR-LP (n = 1). Figure 1 illustrates a declining early mean pacing capture threshold, rising early P-wave amplitudes, and stable impedance for the AR-LP over the 12 months. Mean i2i throughput for communication from the RV to RA and the RA to RV improved from pre-discharge to 3 months and remained stable through the subsequent 9 months (Figure 2). A total of 5 subjects (5 of 36; 13.9%) experienced 7 SADEs (all procedure-related; 2 related to the AR-LP and 2 to the delivery catheter). One non-cardiovascular, non-device, non-procedure related death occurred in the upgrade population. Conclusions: The single to dual-chamber upgrade cohort demonstrated a high upgrade success rate (91.4%), stable atrial and ventricular electrical measurements and consistently high i2i communication throughout the 12 months. AV synchrony (AVS) was not specifically measured in this upgrade cohort, but data from the main DR-LP study suggest that i2i throughput correlates with, but significantly underestimates AVS. Further, the rate of complications was acceptable (13.9%) and limited to the procedure. These data confirm the feasibility, safety and longer-term effectiveness of adding an atrial LP in patients with a pre-existing ventricular LP order to achieve effective dual chamber pacing.Fig. 1: Upgrade Electrical measurementsFig. 2: i2i communication for Upgrades
- Open Access
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
AV synchrony maintained by a dual-chamber leadless pacemaker in real-world conditions
Background/Introduction: A dual-chamber leadless pacemaker system has been developed to provide atrial and ventricular pacing and maintain atrioventricular (AV) synchrony. The device demonstrated an ability to maintain consistent AV synchrony in an in-clinic setting when tested through a series of postures and gaits under some programming restrictions. Assessing AV synchrony within real-world conditions is needed to understand the device’s performance under wider variations in activity and over a longer period. Purpose: Assess a dual-chamber leadless pacemaker’s ability to maintain AV synchrony in an ambulatory environment of daily living under clinically driven programmed settings. Methods: Implanted de novo subjects, who had at least 25% atrial pacing after 3-months post-implant, wore a 12-lead Holter monitor for a minimum of 24 hours during normal daily activities and completed a symptom diary. Devices were programmed to a dual chamber pacing mode and clinically appropriate settings then interrogated pre- and post-assessment. An independent Core Laboratory evaluated AV Synchrony, based on a configurable sampling window approach at repeated intervals, and defined synchronous cycles based on whether PR intervals fell within a 50 ms margin of the programmed Paced AV Delay. Results: Among the 50 subjects who were administered the assessment, 48 of their Holters were analyzable (mean age 71.4 ± 10.9 years; 66.7% male), and 47 subjects had paired device interrogation data available. The analyzable population was predominantly indicated for sinus node dysfunction (83.3%) with a minority indicated for AV block (16.7%). The mean ± standard deviation of the programmed paced AV delay was 260.0 ± 47.6 ms, and mean PR interval was 241.4 ± 35.1 ms. An atrial paced beat and ventricular paced beat were each present in 69.5% and 22.5% of the evaluable cardiac cycles in the population, respectively. Mean AV Synchrony was maintained above 97% (95% CI: 95.5, 98.8) in the entire cohort and was sustained at high rates within each sub-population. Device metrics that diagnose the rate of directional implant-to-implant (i2i) communication also confirmed device data average throughput rates above 90% (Picture 1). There were no reported episodes of oversensing, undersensing, loss of capture, or pauses. Conclusion: Among subjects with standard pacemaker indications, the dual-chamber leadless pacemaker system maintains very high rates of AV synchrony, exceeding i2i throughput, within real-world conditions utilizing clinically appropriate programmed settings.AV Synchrony and i2i by Indication
- 24 May 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (Supplement)
Open AccessAV synchrony maintained by a dual-chamber leadless pacemaker in real-world conditions
Background/Introduction: A dual-chamber leadless pacemaker system has been developed to provide atrial and ventricular pacing and maintain atrioventricular (AV) synchrony. The device demonstrated an ability to maintain consistent AV synchrony in an in-clinic setting when tested through a series of postures and gaits under some programming restrictions. Assessing AV synchrony within real-world conditions is needed to understand the device’s performance under wider variations in activity and over a longer period. Purpose: Assess a dual-chamber leadless pacemaker’s ability to maintain AV synchrony in an ambulatory environment of daily living under clinically driven programmed settings. Methods: Implanted de novo subjects, who had at least 25% atrial pacing after 3-months post-implant, wore a 12-lead Holter monitor for a minimum of 24 hours during normal daily activities and completed a symptom diary. Devices were programmed to a dual chamber pacing mode and clinically appropriate settings then interrogated pre- and post-assessment. An independent Core Laboratory evaluated AV Synchrony, based on a configurable sampling window approach at repeated intervals, and defined synchronous cycles based on whether PR intervals fell within a 50 ms margin of the programmed Paced AV Delay. Results: Among the 50 subjects who were administered the assessment, 48 of their Holters were analyzable (mean age 71.4 ± 10.9 years; 66.7% male), and 47 subjects had paired device interrogation data available. The analyzable population was predominantly indicated for sinus node dysfunction (83.3%) with a minority indicated for AV block (16.7%). The mean ± standard deviation of the programmed paced AV delay was 260.0 ± 47.6 ms, and mean PR interval was 241.4 ± 35.1 ms. An atrial paced beat and ventricular paced beat were each present in 69.5% and 22.5% of the evaluable cardiac cycles in the population, respectively. Mean AV Synchrony was maintained above 97% (95% CI: 95.5, 98.8) in the entire cohort and was sustained at high rates within each sub-population. Device metrics that diagnose the rate of directional implant-to-implant (i2i) communication also confirmed device data average throughput rates above 90% (Picture 1). There were no reported episodes of oversensing, undersensing, loss of capture, or pauses. Conclusion: Among subjects with standard pacemaker indications, the dual-chamber leadless pacemaker system maintains very high rates of AV synchrony, exceeding i2i throughput, within real-world conditions utilizing clinically appropriate programmed settings.AV Synchrony and i2i by Indication
- 3 May 2024
- Published by Elsevier in Heart Rhythm
- Vol. 21 (7) , 1199-1200
LB-469805-02 ONE YEAR SAFETY AND PERFORMANCE OUTCOMES FROM A CLINICAL STUDY OF A DUAL-CHAMBER LEADLESS PACEMAKER SYSTEM
- 3 May 2024
- Published by Elsevier in Heart Rhythm
- Vol. 21 (7) , 1199-1200
LB-469805-02 ONE YEAR SAFETY AND PERFORMANCE OUTCOMES FROM A CLINICAL STUDY OF A DUAL-CHAMBER LEADLESS PACEMAKER SYSTEM
- Open Access
- 5 December 2023
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 12 (1) , 1-9
The economic burden of cardiac implantable electronic device infections in Alberta, Canada: a population-based study using validated administrative data
Background: Cardiac implantable electronic devices (CIED) are being inserted with increasing frequency. Severe surgical site infections (SSI) that occur after device implantation substantially impact patient morbidity and mortality and can result in multiple hospital admissions and repeat surgeries. It is important to understand the costs associated with these infections as well as healthcare utilization. Therefore, we conducted a population-based study in the province of Alberta, Canada to understand the economic burden of these infections. Methods: A cohort of adult patients in Alberta who had CIEDs inserted or generators replaced between January 1, 2011 and December 31, 2019 was used. A validated algorithm of International Classification of Diseases (ICD) codes to identify complex (deep/organ space) SSIs that occurred within the subsequent year was applied to the cohort. The overall mean 12-month inpatient and outpatient costs for the infection and non-infection groups were assessed. In order to control for variables that may influence costs, propensity score matching was completed and incremental costs between those with and without infection were calculated. As secondary outcomes, number of outpatient visits, hospitalizations and length of stay were assessed. Results: There were 26,049 procedures performed during our study period, of which 320 (1.23%) resulted in SSIs. In both unadjusted costs and propensity score matched costs the infection group was associated with increased costs. Overall mean cost was $145,312 in the infection group versus $34,264 in the non-infection group. The incremental difference in those with infection versus those without in the propensity score match was $90,620 (Standard deviation $190,185). Approximately 70% of costs were driven by inpatient hospitalizations. Inpatients hospitalizations, length of stay and outpatient visits were all increased in the infection group. Conclusions: CIED infections are associated with increased costs and are a burden to the healthcare system. This highlights a need to recognize increasing SSI rates and implement measures to minimize infection risk. Further studies should endeavor to apply this work to full economic evaluations to better understand and identify cost-effective infection mitigation strategies.
- 5 December 2023
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 12 (1) , 1-9
Open AccessThe economic burden of cardiac implantable electronic device infections in Alberta, Canada: a population-based study using validated administrative data
Background: Cardiac implantable electronic devices (CIED) are being inserted with increasing frequency. Severe surgical site infections (SSI) that occur after device implantation substantially impact patient morbidity and mortality and can result in multiple hospital admissions and repeat surgeries. It is important to understand the costs associated with these infections as well as healthcare utilization. Therefore, we conducted a population-based study in the province of Alberta, Canada to understand the economic burden of these infections. Methods: A cohort of adult patients in Alberta who had CIEDs inserted or generators replaced between January 1, 2011 and December 31, 2019 was used. A validated algorithm of International Classification of Diseases (ICD) codes to identify complex (deep/organ space) SSIs that occurred within the subsequent year was applied to the cohort. The overall mean 12-month inpatient and outpatient costs for the infection and non-infection groups were assessed. In order to control for variables that may influence costs, propensity score matching was completed and incremental costs between those with and without infection were calculated. As secondary outcomes, number of outpatient visits, hospitalizations and length of stay were assessed. Results: There were 26,049 procedures performed during our study period, of which 320 (1.23%) resulted in SSIs. In both unadjusted costs and propensity score matched costs the infection group was associated with increased costs. Overall mean cost was $145,312 in the infection group versus $34,264 in the non-infection group. The incremental difference in those with infection versus those without in the propensity score match was $90,620 (Standard deviation $190,185). Approximately 70% of costs were driven by inpatient hospitalizations. Inpatients hospitalizations, length of stay and outpatient visits were all increased in the infection group. Conclusions: CIED infections are associated with increased costs and are a burden to the healthcare system. This highlights a need to recognize increasing SSI rates and implement measures to minimize infection risk. Further studies should endeavor to apply this work to full economic evaluations to better understand and identify cost-effective infection mitigation strategies.
- Open Access
Early Real-world Implant Experience with a Helix-fixation Ventricular Leadless Pacemaker
Background Roughly 1 in 6 patients receiving conventional transvenous pacemaker systems experience significant complications within 1 year of implant, mainly due to the transvenous lead and subcutaneous pocket. A new helix-fixation single-chamber ventricular leadless pacemaker (LP) system capable of pre-deployment exploratory electrical mapping is commercially available. Such an LP may mitigate complications while streamlining the implantation. Objectives Evaluate the initial real-world implant experience of the helix-fixation LP following its commercial release. Methods In patients indicated for single-chamber right ventricular pacing, helix-fixation Aveir VR LPs (Abbott, Abbott Park, IL) were implanted using the dedicated loading tool, introducer, and delivery catheter. Implant procedural characteristics, electrical parameters, and any 30-day procedure-related adverse events of consecutive implant attempts were retrospectively evaluated. Results A total of 167 patients with Class I indication for permanent pacing received implants in 4 North American centers (57% male, 70 years old). Pre-fixation electrical mapping of potential sites allowed repositioning to be avoided in 95.7% of patients. Median [interquartile range] LP procedure and fluoroscopy durations were 25.5 min [20.0, 35.0] and 5.7 min [4.0, 9.2], respectively. Pacing capture threshold, sensed R-wave amplitude, and impedance were 0.8 V [0.5, 1.3], 9.0 mV [6.0, 12.0], and 705 Ω [550, 910], respectively. Implantation was successful in 98.8% of patients, with 98.2% free from acute adverse events. Conclusion The initial, real-world experience of the helix-fixation ventricular leadless pacemaker demonstrated safe and efficient implantation with minimal repositioning, viable electrical metrics, and limited acute complications.
Open AccessEarly Real-world Implant Experience with a Helix-fixation Ventricular Leadless Pacemaker
Background Roughly 1 in 6 patients receiving conventional transvenous pacemaker systems experience significant complications within 1 year of implant, mainly due to the transvenous lead and subcutaneous pocket. A new helix-fixation single-chamber ventricular leadless pacemaker (LP) system capable of pre-deployment exploratory electrical mapping is commercially available. Such an LP may mitigate complications while streamlining the implantation. Objectives Evaluate the initial real-world implant experience of the helix-fixation LP following its commercial release. Methods In patients indicated for single-chamber right ventricular pacing, helix-fixation Aveir VR LPs (Abbott, Abbott Park, IL) were implanted using the dedicated loading tool, introducer, and delivery catheter. Implant procedural characteristics, electrical parameters, and any 30-day procedure-related adverse events of consecutive implant attempts were retrospectively evaluated. Results A total of 167 patients with Class I indication for permanent pacing received implants in 4 North American centers (57% male, 70 years old). Pre-fixation electrical mapping of potential sites allowed repositioning to be avoided in 95.7% of patients. Median [interquartile range] LP procedure and fluoroscopy durations were 25.5 min [20.0, 35.0] and 5.7 min [4.0, 9.2], respectively. Pacing capture threshold, sensed R-wave amplitude, and impedance were 0.8 V [0.5, 1.3], 9.0 mV [6.0, 12.0], and 705 Ω [550, 910], respectively. Implantation was successful in 98.8% of patients, with 98.2% free from acute adverse events. Conclusion The initial, real-world experience of the helix-fixation ventricular leadless pacemaker demonstrated safe and efficient implantation with minimal repositioning, viable electrical metrics, and limited acute complications.
- 1 October 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (10) , e012232
Retrieval of Chronically Implanted Dual-chamber Leadless Pacemakers in an Ovine Model
BACKGROUND: The clinical utilization of leadless pacemakers (LPs) as an alternative to traditional transvenous pacemakers is likely to increase with the advent of dual-chamber LP systems. Since device retrieval to allow LP upgrade or replacement will become an important capability, the first such dual-chamber, helix-fixation LP system (Aveir DR; Abbott, Abbott Park, IL) was specifically designed to allow catheter-based retrieval. In this study, the preclinical performance and safety of retrieving chronically implanted dual-chamber LPs was evaluated. METHODS: Atrial and ventricular LPs were implanted in the right atrial appendage and right ventricular apex of 9 healthy ovine subjects. After ≈2 years, the LPs were retrieved using a dedicated transvenous retrieval catheter (Aveir Retrieval Catheter; Abbott) by snaring, docking, and unscrewing from the myocardium. Comprehensive necropsy/histopathology studies were conducted to evaluate device- and procedure-related outcomes. RESULTS: At a median of 1.9 years postimplant (range, 1.8–2.6), all 18 of 18 (100%) LPs were retrieved from 9 ovine subjects without complications. The median retrieval procedure duration for both LPs, from first-catheter-in to last-catheter-out, was 13.3 minutes (range, 2.5–36.4). Postretrieval, all right atrial, and right ventricular implant sites demonstrated minimal tissue disruption, with intact fibrous tissue limited to the distal device body. No significant device-related trauma, perforation, pericardial effusion, right heart or tricuspid valve injury, or chronic pulmonary thromboembolism were observed at necropsy. CONCLUSIONS: This preclinical study demonstrated the safe and effective retrieval of chronically implanted, helix-fixation, dual-chamber LP systems, paving the way for clinical studies of LP retrieval.
- 1 October 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (10) , e012232
Retrieval of Chronically Implanted Dual-chamber Leadless Pacemakers in an Ovine Model
BACKGROUND: The clinical utilization of leadless pacemakers (LPs) as an alternative to traditional transvenous pacemakers is likely to increase with the advent of dual-chamber LP systems. Since device retrieval to allow LP upgrade or replacement will become an important capability, the first such dual-chamber, helix-fixation LP system (Aveir DR; Abbott, Abbott Park, IL) was specifically designed to allow catheter-based retrieval. In this study, the preclinical performance and safety of retrieving chronically implanted dual-chamber LPs was evaluated. METHODS: Atrial and ventricular LPs were implanted in the right atrial appendage and right ventricular apex of 9 healthy ovine subjects. After ≈2 years, the LPs were retrieved using a dedicated transvenous retrieval catheter (Aveir Retrieval Catheter; Abbott) by snaring, docking, and unscrewing from the myocardium. Comprehensive necropsy/histopathology studies were conducted to evaluate device- and procedure-related outcomes. RESULTS: At a median of 1.9 years postimplant (range, 1.8–2.6), all 18 of 18 (100%) LPs were retrieved from 9 ovine subjects without complications. The median retrieval procedure duration for both LPs, from first-catheter-in to last-catheter-out, was 13.3 minutes (range, 2.5–36.4). Postretrieval, all right atrial, and right ventricular implant sites demonstrated minimal tissue disruption, with intact fibrous tissue limited to the distal device body. No significant device-related trauma, perforation, pericardial effusion, right heart or tricuspid valve injury, or chronic pulmonary thromboembolism were observed at necropsy. CONCLUSIONS: This preclinical study demonstrated the safe and effective retrieval of chronically implanted, helix-fixation, dual-chamber LP systems, paving the way for clinical studies of LP retrieval.
- Open Access
- 16 May 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (20) , 1492-1504
Self-Management Support Using Advertising Principles for Older Adults With Low Income at High Cardiovascular Risk: A Randomized Controlled Trial
Background: Self-management education and support (SMES) interventions have modest effects on intermediate outcomes for those at risk of cardiovascular disease, but few studies have measured or demonstrated an effect on clinical end points. Advertising for commercial products is known to influence behavior, but advertising principles are not typically incorporated into SMES design. Methods: This randomized trial studied the effect of a novel tailored SMES program designed by an advertising firm among a population of older adults with low income at high cardiovascular risk in Alberta, Canada. The intervention included health promotion messaging from a fictitious “peer” and facilitated relay of clinical information to patients’ primary care provider and pharmacist. The primary outcome was the composite of death, myocardial infarction, stroke, coronary revascularization, and hospitalizations for cardiovascular-related ambulatory care–sensitive conditions. Rates of the primary outcome and its components were compared using negative binomial regression. Secondary outcomes included quality of life (EQ-5D [EuroQoL 5-dimension] index score), medication adherence, and overall health care costs. Results: We randomized 4761 individuals, with a mean age of 74.4 years, of whom 46.8% were female. There was no evidence of statistical interaction ( P =0.99) or of a synergistic effect between the 2 interventions in the factorial trial with respect to the primary outcome, which allowed us to evaluate the effect of each intervention separately. Over a median follow-up time of 36 months, the rate of the primary outcome was lower in the group that received SMES compared with the control group (incidence rate ratio, 0.78 [95% CI, 0.61 to 1.00]; P =0.047). No significant between-group changes in quality of life over time were observed (mean difference, 0.0001 [95% CI, −0.018 to 0.018]; P =0.99). The proportion of participants who were adherent to medications was not different between the 2 groups ( P =0.199 for statins and P =0.754 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers). Overall adjusted health care costs did not differ between those receiving SMES and the control group ($2015 [95% CI, −$1953 to $5985]; P =0.320). Conclusions: For older adults with low income, a tailored SMES program using advertising principles reduced the rate of clinical outcomes compared with usual care. The mechanisms of improvement are unclear and further studies are required. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02579655.
- 16 May 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (20) , 1492-1504
Open AccessSelf-Management Support Using Advertising Principles for Older Adults With Low Income at High Cardiovascular Risk: A Randomized Controlled Trial
Background: Self-management education and support (SMES) interventions have modest effects on intermediate outcomes for those at risk of cardiovascular disease, but few studies have measured or demonstrated an effect on clinical end points. Advertising for commercial products is known to influence behavior, but advertising principles are not typically incorporated into SMES design. Methods: This randomized trial studied the effect of a novel tailored SMES program designed by an advertising firm among a population of older adults with low income at high cardiovascular risk in Alberta, Canada. The intervention included health promotion messaging from a fictitious “peer” and facilitated relay of clinical information to patients’ primary care provider and pharmacist. The primary outcome was the composite of death, myocardial infarction, stroke, coronary revascularization, and hospitalizations for cardiovascular-related ambulatory care–sensitive conditions. Rates of the primary outcome and its components were compared using negative binomial regression. Secondary outcomes included quality of life (EQ-5D [EuroQoL 5-dimension] index score), medication adherence, and overall health care costs. Results: We randomized 4761 individuals, with a mean age of 74.4 years, of whom 46.8% were female. There was no evidence of statistical interaction ( P =0.99) or of a synergistic effect between the 2 interventions in the factorial trial with respect to the primary outcome, which allowed us to evaluate the effect of each intervention separately. Over a median follow-up time of 36 months, the rate of the primary outcome was lower in the group that received SMES compared with the control group (incidence rate ratio, 0.78 [95% CI, 0.61 to 1.00]; P =0.047). No significant between-group changes in quality of life over time were observed (mean difference, 0.0001 [95% CI, −0.018 to 0.018]; P =0.99). The proportion of participants who were adherent to medications was not different between the 2 groups ( P =0.199 for statins and P =0.754 for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers). Overall adjusted health care costs did not differ between those receiving SMES and the control group ($2015 [95% CI, −$1953 to $5985]; P =0.320). Conclusions: For older adults with low income, a tailored SMES program using advertising principles reduced the rate of clinical outcomes compared with usual care. The mechanisms of improvement are unclear and further studies are required. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02579655.